P=N/A, N=83, Not yet recruiting, The Affiliated Zhongda Hospital of Southeast University; The Affiliated Zhongda Hospital of Southeast University

P3, N=120, Not yet recruiting, Aurion Biotech

Finally, upstream-regulator analysis (iPathwayGuide) and gene-centric perturbation mapping (Gene2Drug) nominated candidate targeted and repurposable agents predicted to reverse the metastatic expression phenotype and flagged drugs unlikely to provide benefit, yielding a prioritized, testable therapeutic shortlist which includes fasudil and spaglumic acid. Convergent, domain-specific mutational patterns in highly mutated genes such as ZNF273 and CLCA1 define a molecular signature that could stratify metastatic risk in low-grade pNETs. Collectively, our data reframe metastasis in MEN1-wild-type low-grade pNETs as a property of pathway state rather than mutation quantity and provide a translational blueprint for biomarker-guided therapy development focused on Calcium, WNT, and KRAS/PI3K hubs.

P3, N=489, Active, not recruiting, Alcon Research | Recruiting --> Active, not recruiting

Its mechanism of action is distinctively linked to the restoration of genes critical to adherens and tight junction integrity. Given its derivation from the clinically viable fasudil, fasudil-D-6h presents a strong translational potential as a novel therapeutic agent for TNBC.

P4, N=30, Active, not recruiting, Mayo Clinic

We demonstrate that the E3 ligase UBE2O catalyzes dual-site monoubiquitination of NLRP6: at K680-687 to drive oligomerization via a conformational change, and at K115/130 within the nuclear localization signal to enforce cytoplasmic sequestration through steric hindrance. Furthermore, the UBE2O inhibitor arsenic trioxide suppresses NLRP6-dependent interleukin (IL)-18 secretion in acute promyelocytic leukemia (APL) patients. Thus, UBE2O-mediated dual-site monoubiquitination emerges as a central mechanism licensing NLRP6 inflammasome activation, revealing a new target for modulating intestinal immunity.

P1/2, N=21, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=93 --> 21 | Trial completion date: May 2027 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Dec 2025; Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.

P4, N=30, Not yet recruiting, Oregon Health and Science University | Initiation date: Oct 2025 --> Jan 2026

P1, N=6, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

P3, N=60, Recruiting, Stanford University | Trial completion date: Aug 2028 --> Nov 2028 | Trial primary completion date: Aug 2027 --> Nov 2027

P1/2, N=97, Completed, Aurion Biotech | Active, not recruiting --> Completed | Trial completion date: Oct 2025 --> Apr 2025